PLEASE JOIN US FOR A CLINICAL DISCUSSION ON A NEW, FDA-APPROVED CLL TREATMENT

GAZYVA FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

Indication

GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).

Discussion Objectives:

- Review the efficacy and safety of GAZYVA in combination with chlorambucil as shown in CLL11
- Explore the proposed mechanism of action of GAZYVA
- Review the dosing and administration of GAZYVA in previously untreated patients with CLL

Presented by:

Anthony R. Mato, M.D., M.S

John Theurer Cancer Center

Hackensack, NJ

Date:

Tuesday April 1, 2014

Hosted by:

Jeannette Reed

Genentech

Location:

Steakhouse 85

85 Church Street

New Brunswick, NJ 08901

Schedule of events:

5:30 pm Registration

6:00 pm Program and dinner

Registration:

Please register for this event by 3/27/2014

Register online at www.genersvp.com with reference event code PRF42784

or RSVP to Jeannette Reed 973-615-0397 or reedj8@gene.com

Boxed WARNINGS: HEPATITIS B VIRUS REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY

- **Hepatitis B Virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients receiving CD20-directed cytolytic antibodies, including GAZYVA. Screen all patients for HBV infection before treatment initiation. Monitor HBV positive patients during and after treatment with GAZYVA. Discontinue GAZYVA and concomitant medications in the event of HBV reactivation**
- **Progressive Multifocal Leukoencephalopathy (PML) including fatal PML, can occur in patients receiving GAZYVA**

This is a Genentech promotional activity. Note: No continuing medical education (CME) credit will be awarded.

Please see Important Safety Information on back. For additional Important Safety Information, please see the accompanying full Prescribing Information, including Boxed WARNINGS.

GAZYVA™
obinutuzumab injection

PLEASE JOIN US FOR A CLINICAL DISCUSSION ON A NEW, FDA-APPROVED CLL TREATMENT

We look forward to your participation!

Minnesota, Vermont, the **Department of Defense,** and the **Department of Veterans Affairs** have restrictions on receiving in-kind benefits (e.g., meals, valet parking) at company-sponsored events. You are accountable for understanding such restrictions and complying with them. If you are licensed in or affiliated with any of these states or federal agencies, Genentech policies may restrict you from consuming any portion of the Genentech-sponsored meal at this program or from receiving any other in-kind benefit from Genentech (e.g., valet parking) in connection with the program.

When you RSVP please indicate whether you will accept or opt out of Genentech's in-kind benefits (e.g., meals, valet parking) at the program. If you choose to opt out you may either pay for the meal and parking on your own, or not consume anything at the program. For all program attendees who receive Genentech's in-kind benefits at this program, Genentech will report the attendee's name and the value received as required by federal and state disclosure laws (for more information on the federal law please visit http://sunshine.gene.com). The meal cost may vary by event location and be up to $125 per person (exceptions may apply).

Important Safety Information

- **Infusion Reactions:** GAZYVA can cause severe and life-threatening infusion reactions
- **Tumor Lysis Syndrome (TLS):** TLS can occur within 12-24 hours after the first infusion
- **Infections:** Serious bacterial, fungal, and new or reactivated viral infections can occur during and following GAZYVA therapy
- **Neutropenia and Thrombocytopenia:** Severe neutropenia and severe thrombocytopenia can occur in patients treated with GAZYVA in combination with chlorambucil

Additional Important Safety Information

- The most common adverse reactions (incidence ≥10%) were: infusion reactions, neutropenia, thrombocytopenia, anemia, pyrexia, cough, and musculoskeletal disorders

You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see the accompanying full Prescribing Information for additional Important Safety Information, including Boxed WARNINGS.

Genentech
A Member of the Roche Group

MIX
Paper from responsible sources
FSC® XXXXXX

GAZYVA™
obinutuzumab injection